Haythem Ali

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process

Cathy Bennett, Nimish Vakil, Jacques Bergman et al. · Gastroenterology · 2012 · 378 citations · Full text

Medicine, Oncology, Surgery +16

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Martin Schlumberger, Rossella Elisei, Stefan Müller et al. · Annals of Oncology · 2017 · 239 citations · Full text

Medicine, Oncology, Pharmacology +6

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Denise A. Yardley, Rob Coleman, PierFranco Conte et al. · Annals of Oncology · 2018 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15